SNAPC3: A Small Nuclear RNA-Activating Complex Polypeptide 3 as a Drug Target and Biomarker

Target Name: SNAPC3

NCBI ID: G6619

SNAPC3

SNAPC3: A Small Nuclear RNA-Activating Complex Polypeptide 3 as a Drug Target and Biomarker

Introduction

Small nuclear RNA-activating complex polypeptide 3 (SNAPC3) is a protein that plays a critical role in the regulation of gene expression in the nucleus. It is a 26-kDa protein that contains a nucleotide-binding oligomerization domain (NBO), a nucleotide -binding domain (NBD), and a carboxy-terminal domain (CTD). SNAPC3 is highly conserved, with significant sequence identity to other known transcription factors, including p53, NF-Y2, and HIF1伪. It is expressed in a variety of tissues and cells, including liver, muscle, heart, and cancer cells. The functions of SNAPC3 in cell biology are still being fully understood, but it is known to play a key role in the regulation of gene expression, DNA replication, and apoptosis.

Drug Resistance and Cancer

SNAPC3 has been implicated in the development and progression of various cancers, including liver cancer, breast cancer, and colorectal cancer. In cancer cells, SNAPC3 is overexpressed, and its functions are often disrupted. This overexpression leads to the activation of oncogenic signaling pathways, such as the PI3K/Akt signaling pathway, which promotes the growth and survival of cancer cells.

Furthermore, SNAPC3 has been shown to be involved in the regulation of DNA replication in cancer cells. In fact, SNAPC3 has been shown to interact with the DNA-binding domain of the transcription factor, p53. This interaction may modulate the transcriptional activity of p53 and contribute to the regulation of gene expression in cancer cells.

Disease Models and Therapeutic Strategies

Based on the findings above, SNAPC3 is a potential drug target and biomarker for cancer therapy. One approach to targeting SNAPC3 is to inhibit its activity using small molecule inhibitors. Several inhibitors have been shown to interact with SNAPC3 and have been developed as potential therapeutic agents for cancer.

One of the most promising inhibitors is NB-1026, which is a small molecule that binds to the NBO of SNAPC3. NB-1026 is a potent inhibitor of SNAPC3 activity, and it has been shown to decrease the transcriptional activity of SNAPC3 in cancer cells . Additionally, NB-1026 has been shown to inhibit the growth of SNAPC3-positive cancer cells in a xenograft model.

Another inhibitor that has been shown to interact with SNAPC3 is the small molecule drug, K552a, which is a inhibitor of the protein phosphorylase, PAK1. PAK1 is a key regulator of SNAPC3 activity, and K552a has been shown to inhibit its activity in cancer cells.

Conclusion

SNAPC3 is a protein that plays a critical role in the regulation of gene expression in the nucleus. Its functions in cancer biology are still being fully understood, but it is known to be involved in the development and progression of various cancers. In addition, SNAPC3 has been shown to play a key role in the regulation of DNA replication in cancer cells.

The development of small molecule inhibitors that target SNAPC3 is a promising approach to cancer therapy. NB-1026 and K552a are two examples of inhibitors that have been shown to interact with SNAPC3 and have potential as therapeutic agents for cancer. Further research is needed to fully understand the functions of SNAPC3 in cancer biology and to develop more effective therapies based on this protein.

Protein Name: Small Nuclear RNA Activating Complex Polypeptide 3

Functions: Part of the SNAPc complex required for the transcription of both RNA polymerase II and III small-nuclear RNA genes. Binds to the proximal sequence element (PSE), a non-TATA-box basal promoter element common to these 2 types of genes. Recruits TBP and BRF2 to the U6 snRNA TATA box

The "SNAPC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNAPC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets